The winding down of a 2011 development deal between Zacharon Inc. and Pfizer Inc. gave erstwhile suitor BioMarin Pharmaceutical Inc. a new opening to buy the company.

The acquisition is also the latest in a string of endeavors by enzyme replacement therapy companies looking to crack the blood-brain barrier.